MedTrace Logo

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

NCT00272454 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2009-12-16

No results posted yet for this study

Summary

The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.

Conditions

  • Cerebral Infarction

Interventions

DRUG

Cilostazol

DRUG

Aspirin

Sponsors & Collaborators

  • Seoul National University Boramae Hospital

    collaborator OTHER

  • Korea Otsuka International Asia Arab Co., Ltd.

    collaborator UNKNOWN

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yong-Seok Lee, M.D., PhD · Department of Neurology, Seoul National University Boramae Hospital, College of Medicine, Seoul National University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2008-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272454 on ClinicalTrials.gov